Jefferies Group LLC reiterated their hold rating on shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in a research report released on Wednesday. Jefferies Group LLC currently has a $18.00 price objective on the stock.
Other analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Myriad Genetics from a hold rating to a sell rating in a research note on Tuesday, October 25th. Deutsche Bank AG reissued a sell rating and set a $15.00 target price on shares of Myriad Genetics in a research note on Wednesday, January 18th. Stephens lowered shares of Myriad Genetics from an overweight rating to an equal weight rating in a research note on Wednesday, November 2nd. TheStreet lowered shares of Myriad Genetics from a hold rating to a sell rating in a research note on Tuesday, November 1st. Finally, Ladenburg Thalmann Financial Services raised shares of Myriad Genetics from a sell rating to a neutral rating in a research note on Wednesday, February 8th. Four research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has assigned a buy rating to the company’s stock. Myriad Genetics presently has an average rating of Hold and an average price target of $27.64.
Shares of Myriad Genetics (NASDAQ:MYGN) opened at 15.99 on Wednesday. Myriad Genetics has a 1-year low of $15.15 and a 1-year high of $39.74. The firm’s 50-day moving average is $16.35 and its 200-day moving average is $19.53. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 18.07 and a beta of 0.26.
Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings data on Tuesday, February 7th. The company reported $0.26 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.02. Myriad Genetics had a net margin of 8.08% and a return on equity of 12.02%. The business had revenue of $196.50 million for the quarter, compared to analysts’ expectations of $189.72 million. During the same quarter in the previous year, the business posted $0.45 earnings per share. The business’s revenue was up 1.7% compared to the same quarter last year. Analysts forecast that Myriad Genetics will post $1.01 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Myriad Genetics’ (MYGN) Hold Rating Reiterated at Jefferies Group LLC” was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are viewing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright law. The legal version of this report can be read at http://sleekmoney.com/myriad-genetics-mygn-hold-rating-reiterated-at-jefferies-group-llc/1657589.html.
Several hedge funds have recently added to or reduced their stakes in MYGN. Bank of Montreal Can purchased a new stake in Myriad Genetics during the second quarter valued at approximately $3,484,000. Strs Ohio increased its position in Myriad Genetics by 9.2% in the second quarter. Strs Ohio now owns 40,200 shares of the company’s stock valued at $1,230,000 after buying an additional 3,400 shares during the period. Nordea Investment Management AB bought a new position in Myriad Genetics during the second quarter valued at about $607,000. BB&T Corp increased its position in Myriad Genetics by 3.8% in the second quarter. BB&T Corp now owns 131,297 shares of the company’s stock valued at $4,018,000 after buying an additional 4,853 shares during the period. Finally, Airain ltd increased its position in Myriad Genetics by 173.7% in the second quarter. Airain ltd now owns 102,590 shares of the company’s stock valued at $3,139,000 after buying an additional 65,105 shares during the period.
About Myriad Genetics
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/myriad-genetics-mygn-hold-rating-reiterated-at-jefferies-group-llc/1657589.html
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.